Methods-Breast cancer specimens were surgically obtained from 119 previously untreated patients. For comparison, oestrogen receptor was measured from cytosol fractions using an established oestrogen receptor enzyme immunoassay (ER-EIA) method. Oestrogen receptor "H-scores" were obtained from the ER-IHA after antigen retrieval using microwave treatment. Where discrepancies occurred between the two methods, further immunohistochemistry was performed using the H222 antibody from the Abbott Laboratories ER-ICA kit. Results-The correlation between the two methods was non-linear, but despite this there was an 86% concordance between ER-EIA and ER-IHA using the lD5 ER antibody. Fifty four per cent of tumours (64/119) were oestrogen receptor positive and 32% (38/119) were negative by both assays. A mismatch between the ER-EIA and ER-IHA occurred in 17 cases. Seven tumours were IHA positive but EIA+, but five of these were borderline negative by EIA, having values of >5 and <10 fmolmg protein. Ten tumours were IHA negative and EIA+; four of these tumours were completely negative by IHA in the section studied. A further IHA assay, carried out on the 17 tumour mismatches with H222 antibody, showed that three tumours remained substantially discordant. These three tumours were strongly positive with the lD5 antibody and negative with the H222 antibody. Two of these discordant tumours were of the rare ER negative and PgR positive phenotype and may contain oestrogen receptor that is of biological interest but which lacks the hormone binding epitope. Comparison of immunohistochemwcal assay with enzyme immunoassay use of the H222 antibody in this context has met with varying degrees of reported success, and inconsistencies between and within laboratories have been common.'0 The lack of consistency could be due to differing pronase activity between batches, although with optimisation of predigestion techniques, individual laboratories have got the H222 antibody to work well and consistently.
Because of these problems, however, we investigated microwave pretreatment as an alternative and more reliable method of antigen retrieval, in addition to using a new antioestrogen receptor antibody (clone 1D5), directed against the N-terminal region of the oestrogen receptor (Dako)," which is considerably cheaper than H222.
Methods
The study was carried out on 119 untreated primary breast carcinomas. Mastectomy or excision biopsy specimens were delivered fresh immediately after resection, and were processed immediately.
A portion of tumour, about 200 mg in size, was snap frozen in liquid nitrogen immediately after dissection from the breast, and stored at -80'C before analysis for oestrogen receptor using enzyme immunoassay. The remainder of the tumour was fixed for about 24 hours in 10% buffered formalin. The tissues were embedded in paraffin wax following a routine processing procedure which did not exceed 60°C. As far as possible, the portion of tumour taken for ER-EIA was immediately adjacent to the paraffin wax embedded tumour from which sections were cut.
Sections of 3 ,um were cut from the paraffin wax embedded tumours on to slides coated with APES (3-aminopropyltriethoxysilane; Sigma). The sections were air dried overnight in an oven at 37°C, and one section stained with haematoxylin and eosin for light microscopic assessment.
OESTROGEN RECEPTOR ENZYME IMMUNOASSAY (ER-EIA)
Before cytosol preparation, fat, blood, and necrotic tissue were discarded from each sample and a piece of tumour between 01 and 0-2 g was taken. The tissue was finely chopped, weighed, and transferred to the Teflon container of a microdismembrator (Braun Medical Ltd.). The tissue was pulverised for one minute after being cooled in liquid nitrogen for one minute. The powdered tumour was reconstituted 1:8 weight:volume in iced TRIS/molybdate buffer (5 mM sodium molybdate, 10 mM monothioglycerol, 1 mM dipotassium chloride EDTA, 3 mM sodium azide, and 10 mM TRIS, pH 7A4).
The homogenate was centrifuged at 4°C for 20 minutes at 2000 x g after which the cytosol fraction was removed and diluted 1 in 5 in TRIS/molybdate buffer for protein assay using the Bio-Rad method with a bovine gamma globulin standard.
An aliquot of the cytosol was diluted to give a protein concentration of 1 to 2 mg/ml. The oestrogen receptor concentrations in the diluted cytosols were determined using the ER-EIA kit from Abbott Diagnostics according to the manufacturer's instructions and values 2 10 fmol/mg protein were regarded as positive.
1D5 ER IMMUNOHISTOCHEMICAL METHOD (ER-IHA-1D5)
The paraffin wax embedded sections were warmed on a hot plate and then dewaxed in xylene and rehydrated through a descending series of alcohols. Unless otherwise stated all the following reagents were obtained from Dako Laboratories and incubations carried out at room temperature. The sections were placed in a plastic dish filled with 10 mM citrate buffer, pH 6-0, and microwaved (750 watts) on full power for two five minute intervals, ensuring that the sections did not dry out at any time. The sections were then washed in tap water and phosphate buffered saline (PBS) (pH7A4) and incubated in 10% hydrogen peroxide/PBS for 15 minutes, and a 1 in 5 dilution of normal rabbit serum for five minutes. The normal rabbit serum was tapped off and the sections were then incubated for two hours with a 1 in 100 dilution of monoclonal anti-human ER antibody 1D5. The sections were washed and incubated with a 1 in 100 dilution of biotinylated rabbit antimouse immunoglobulin for 45 minutes. After washing in PBS, the sections were incubated with a 1 in 200 dilution of horseradish peroxidase conjugated streptavidin complex for one hour. A solution of 0 05% 3,3' diaminobenzidine (Sigma) dissolved in dimethyl formamide, plus 100 ,ul of 30 volumes hydrogen peroxide/100 ml PBS, was used to develop the peroxidase activity in the sections for 10 minutes. The sections were then washed in running water, counterstained lightly with Mayer's haematoxylin, blued in tap water, dehydrated, cleared, and mounted. Previously identified strongly oestrogen receptor positive paraffin wax embedded tumours were used as controls, with the negative control being achieved by omission of the primary antibody.
H222 ER IMMUNOHISTOCHEMICAL METHOD (ER-IHA-H222)
Serial sections of tissue adjacent to those stained with 1D5 were taken for staining with H222. The method was the same as for the ER-IHA-1D5 described above, with two exceptions. The sections were not microwaved, but instead, following incubation with H202, were digested with a 0 03% solution of XXV protease enzyme (Sigma) in PBS for nine minutes at 40°C and rinsed in PBS at 4°C. After incubation with a 1 in 5 dilution of normal rabbit serum for five minutes, sections were incubated overnight with rat primary monoclonal anti-human oestrogen receptor antibody H222 (Abbott Diagnostics ER-ICA Kit). The other difference in the immunohistochemical protocol was that the incubation time with the streptavidin biotinylated horseradish peroxidase complex was half an hour shorter. 
R-Results
The age of the patients ranged from 31 to 78 years (median 56 years). The mean value for the ER-EIA assay was 60-0 fmol/mg protein (median 25 fmol/mg protein). The immunohistochemical staining with the 1D5 antibody produced uniform nuclear staining (fig 1) . (fig 3) . This is probably mainly due to there not being a linear correlation between protein concentration and the intensity of the colour developed.
Using the cut offs described, there were 17 tumours in which the ER-IHA and ER-EIA mismatched. By repeating the assay in these tumours with both 1D5 and H222, four of these tumours remained completely negative by IHA in the section studied. The EIA values in these four tumours was between 10 and 18 fmol/mg protein, which is borderline, and in this situation the IHA result may have been due to sampling of an oestrogen receptor negative area. Half of the remaining 6 EIA positive IHA negative tumours had EIA values greater than 50 fmol/mg protein, and in these tumours the H222 score was between 10 and 31. Therefore, several of the apparent discrepancies between ER-IHA and ER-EIA may be explained by borderline results. A further potential explanation for these EIA positive IHA negative discrepancies could be oestrogen receptor positive benign elements present in the tumour which in a tumour homogenate would give an EIA positive result.
Three tumours remained discordant following reassessment. These tumours, which had EIA values of 0, 6, and 8 fmol/mg protein, were strongly positive with 1D5 and negative with the H222 antibody. The ER-EIA technique uses a sandwich method with the D547 antibody (against the central part of the receptor) in the solid phase and the H222 antibody (against the hormone binding domain) labelled to the peroxidase enzyme.
Thus, both the ER-EIA and ER-IHA-H222 assays require an intact hormone binding domain to detect oestrogen receptor protein.
There are a substantial number of reports of oestrogen receptor molecular variants which lack one part or other of the full molecule. Receptor with a mutated or absent ligand binding domain might be negative by these two assays, but positive by the ER-IHA-1D5 directed against the N-terminal of the receptor. Such a receptor variant has been suggested as existing following the discovery of variant forms of messenger RNA (mRNA) in human breast cancers in which the exon-5 region, coding for part of the ligand binding domain, has been spliced out during transcription.22 These variant forms of mRNA are particularly abundant in the rare tumour phenotype which is ER negative by conventional assay, but which expresses high levels of the oestrogen-dependent protein PgR. It is interesting to note, therefore, that two of the three remaining discordant tumours in our series which are only positive by ER-IHA-1D5 are of the rare ER negative PgR positive phenotype. Thus, this antibody may be of potential use in investigating variant forms of oestrogen receptor protein which are not detected by conventional assays.
In conclusion, the ER-IHA which we have described using the 1D5 antibody shows good concordance with the established biochemical ER-EIA assay. Discrepancies may occur among tumours with borderline oestrogen receptor ER-EIA values. The use of separate monoclonal antibodies directed against different parts of the receptor may also be of value in the investigation of variant forms of oestrogen receptor.
